1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Multi-step process: Pre-proposal due April 1, 2026 (4:59pm ET); Full proposal due July 8, 2026 by invitation only. deadline_found is the final full proposal date.
"Canine Annual (Established Investigator, First Award, Pilot Study, Fellowship Training)" is currently closed and not accepting applications.
The Canine Annual grants are a set of research funding opportunities from Morris Animal Foundation that support hypothesis-driven research advancing canine health and welfare. Award categories include Established Investigator awards (averaging ~,000, up to 36 months), First Award grants (up to ,000 over 24 months), Pilot Study grants (up to ,000 over 12 months), and Fellowship Training awards (up to ,000 over 24 months).
The pre-proposal deadline is April 1, 2026, with full proposals due July 8, 2026. Only one application per principal investigator per cycle is accepted. Use of data or samples from the Golden Retriever Lifetime Study is strongly encouraged or required for some award categories.
Eligible applicants are established and early-career investigators conducting canine health and welfare research.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
For You Search Deep Research Favorites Profile Atom | Canine Health and Welfare Established Investigator, First Award, Pilot Study, and Fellowship Training Awards Canine Health and Welfare Established Investigator, First Award, Pilot Study, and Fellowship Training Awards Funder: Morris Animal Foundation Due Dates: April 1, 2026 (Pre-proposal deadline) | July 8, 2026 (Full proposal deadline) Funding Amounts: Up to $145,000 for Fellowship Training (24 months); up to $120,000 for First Award (24 months); up to $20,000 for Pilot Study (12 months); Established Investigator awards average ~$100,000 (up to 36 months, no strict cap).
Summary: Supports hypothesis-driven research projects advancing canine health and welfare, including opportunities for established and early-career investigators, pilot studies, and fellowship trainees. Key Information: Only one application per PI per cycle; use of Golden Retriever Lifetime Study data/samples is strongly encouraged or required for some awards.
According to the current listing, eligibility includes: Applicants must hold relevant doctoral degrees (PhD, DVM, DVSc). Only one application per Principal Investigator allowed per cycle. Fellowship trainees must devote at least 75% effort to the project. Confirm the full requirements in the official notice before applying.
The current listing shows up to $145,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was July 8, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Canine Annual (Established Investigator, First Award, Pilot Study, Fellowship Training) is funded by Morris Animal Foundation. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
The Complement-ARIE program funds organ-on-chip, computational biology, and human tissue models to replace animal research. A deep look at what it means for funding strategy.
Read articleNIH launched Complement-ARIE with $150M to develop organ-on-chip, AI models, and other NAMs that simulate human biology. What biotech researchers and grant seekers need to know.
Read articleThe Complement-ARIE program funds seven technology centers to develop human-based models that complement animal research. What it means for drug developers, academic researchers, and the regulatory pipeline.
Read article